Researchers Find Additional Benefits of Novartis AG's Heart Failure Drug Entresto
Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years
The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — which is a reduced capability to pump blood from the heart — that took sacubitril-valsartan increased their life expectancy of one and a half to two years, compared to current treatments.
The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — which is a reduced capability to pump blood from the heart — that took sacubitril-valsartan increased their life expectancy of one and a half to two years, compared to current treatments.